All News

The MiniArc Single-Incision Sling System (American Medical Systems, Minnetonka, MN) for female stress urinary incontinence offers efficacy rates of 90.6% for negative cough stress test and 84.5% for the 1-hour pad weight test at 12 months, according to a prospective, multicenter study.

An ultrasensitive PSA test using nanoparticle-based technology may be able to definitively predict whether the cancer is cured long term or if it will recur, new research from Northwestern University?s Feinberg School of Medicine and the University International Institute for Nanotechnology, Chicago shows.

The Centers for Medicare and Medicaid Services has launched a National Coverage Analysis (NCA) of sipuleucel-T (Provenge), a recently approved cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer. The agent is the first in a new therapeutic class known as autologous cellular immunotherapies.

FDA has approved cabazitaxel (Jevtana), a chemotherapeutic agent used in combination with prednisone for treatment of advanced, hormone-refractory prostate cancer following docetaxel (Taxotere)-based treatment.

When I talked to urologists at the recently concluded AUA annual meeting about Richard D. Williams, MD, they all described Dick Williams, the person, first: Unassuming. Dedicated. Soft-spoken. Genuine.

The 105th AUA annual meeting provided important research advances on several fronts. Two themes emerged across a number of presentations: utilization of various diagnostic techniques and treatment modalities (both overuse and underuse); and interrelationships among various non-urologic medical conditions.

Most urologists' professional conduct is impeccable, but there is an occasional physician whose attitude and behavior make life at work difficult for everyone.